What this Trial Is About

Psoriasis is a chronic immune-related skin condition marked by red, itchy plaques. This research focuses on patients with moderate to severe psoriasis who are receiving treatment with anti-interleukin-23 (IL-23) biologic drugs. Although IL-23 blockers are effective, some patients experience relapses or resistant skin areas. The study aims to identify the specific immune cells producing key signaling proteins called cytokines that contribute to the persistence or return of psoriatic lesions during this treatment. Participants will undergo a skin biopsy procedure where a small sample (6 mm punch biopsy) is taken from the psoriatic skin lesion that is resistant to treatment or has flared during anti-IL-23 therapy. This allows researchers to study the immune cells within the affected skin. The study includes patients who have been treated with anti-IL-23 drugs for at least six months and currently have active resistant or recurring lesions. Throughout the study, which lasts approximately one year, researchers will analyze the immune cells in the skin samples to determine the source of important cytokines involved in the disease's persistence or relapse. Participants will provide informed consent and undergo evaluations to ensure the collection of relevant data. The study is designed to improve understanding of immune activity in psoriasis during anti-IL-23 treatment and may inform future therapeutic strategies.

Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)